Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDP-101 in Chinese Patients With Plasma Cell Disorders Including Multiple Myeloma
NCT07529782Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Cyclic Peptides, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDP-101 in multiple myeloma (MM) and plasma cell neoplasm, sponsored by Huadong Medicine. Primary endpoint: Dose-Limiting Toxicity at 21 days. Started Mar 2026; status: recruiting.
02
Drugs
HDP-101
03
Conditions
multiple myeloma (MM)plasma cell neoplasm
Beyond the preview
Go deeper on NCT07529782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529782.